Ice1234
2021-08-28
[强]
U.S. resumes supply of Lilly's COVID-19 antibody combo to some states
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
1
6
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":813958354,"tweetId":"813958354","gmtCreate":1630123796978,"gmtModify":1704956319142,"author":{"id":3576662504844996,"idStr":"3576662504844996","authorId":3576662504844996,"authorIdStr":"3576662504844996","name":"Ice1234","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":4,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p><span>[强] </span></p></body></html>","htmlText":"<html><head></head><body><p><span>[强] </span></p></body></html>","text":"[强]","highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/813958354","repostId":2162707824,"repostType":4,"repost":{"id":"2162707824","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1630104635,"share":"https://www.laohu8.com/m/news/2162707824?lang=&edition=full","pubTime":"2021-08-28 06:50","market":"us","language":"en","title":"U.S. resumes supply of Lilly's COVID-19 antibody combo to some states","url":"https://stock-news.laohu8.com/highlight/detail?id=2162707824","media":"Reuters","summary":"Aug 27 (Reuters) - U.S. health officials on Friday decided to resume the supply of Eli Lilly's COVID","content":"<p>Aug 27 (Reuters) - U.S. health officials on Friday decided to resume the supply of Eli Lilly's COVID-19 antibody cocktail to states where variants resistant to it are low, saying the therapy could work against the fast-spreading Delta variant based on lab studies.</p>\n<p>The Department of Health and Human Services narrowed the scope of authorization for the dual-antibody therapy, bamlanivimab and etesevimab, to states including Colorado, Connecticut and Illinois, Indiana.</p>\n<p>With the Delta variant becoming the dominant strain, the prevalence of variants resistant to the therapy is steadily decreasing, the agency said</p>\n<p>Based on lab tests, the drugs administered together are expected to retain activity against the Delta variant, but not against Delta plus and variants first identified in Brazil, South Africa and Colombia, it said.</p>\n<p>The department had in June paused its distribution after the therapy failed to show effectiveness against the coronavirus variants that were first identified in Brazil and South Africa.</p>\n<p>The supply of standalone etesevimab to be paired with existing supply of bamlanivimab is also being resumed to some states.</p>\n<p>Regeneron's antibody therapy REGEN-COV, and GlaxoSmithKline Plc and partner Vir Biotechnology's</p>\n<p>sotrovimab may be used in all states, territories, and U.S. jurisdictions as they are likely to be effective against most variants including Delta, the agency said.</p>\n<p>Bamlanivimab and etesevimab, REGEN-COV and sotrovimab are authorized for use in people 12 years and above with mild-to-moderate infection and are at high risk for progression to severe COVID-19.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. resumes supply of Lilly's COVID-19 antibody combo to some states</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. resumes supply of Lilly's COVID-19 antibody combo to some states\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-08-28 06:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Aug 27 (Reuters) - U.S. health officials on Friday decided to resume the supply of Eli Lilly's COVID-19 antibody cocktail to states where variants resistant to it are low, saying the therapy could work against the fast-spreading Delta variant based on lab studies.</p>\n<p>The Department of Health and Human Services narrowed the scope of authorization for the dual-antibody therapy, bamlanivimab and etesevimab, to states including Colorado, Connecticut and Illinois, Indiana.</p>\n<p>With the Delta variant becoming the dominant strain, the prevalence of variants resistant to the therapy is steadily decreasing, the agency said</p>\n<p>Based on lab tests, the drugs administered together are expected to retain activity against the Delta variant, but not against Delta plus and variants first identified in Brazil, South Africa and Colombia, it said.</p>\n<p>The department had in June paused its distribution after the therapy failed to show effectiveness against the coronavirus variants that were first identified in Brazil and South Africa.</p>\n<p>The supply of standalone etesevimab to be paired with existing supply of bamlanivimab is also being resumed to some states.</p>\n<p>Regeneron's antibody therapy REGEN-COV, and GlaxoSmithKline Plc and partner Vir Biotechnology's</p>\n<p>sotrovimab may be used in all states, territories, and U.S. jurisdictions as they are likely to be effective against most variants including Delta, the agency said.</p>\n<p>Bamlanivimab and etesevimab, REGEN-COV and sotrovimab are authorized for use in people 12 years and above with mild-to-moderate infection and are at high risk for progression to severe COVID-19.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"REGN":"再生元制药公司","LLY":"礼来","VIR":"Vir Biotechnology, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2162707824","content_text":"Aug 27 (Reuters) - U.S. health officials on Friday decided to resume the supply of Eli Lilly's COVID-19 antibody cocktail to states where variants resistant to it are low, saying the therapy could work against the fast-spreading Delta variant based on lab studies.\nThe Department of Health and Human Services narrowed the scope of authorization for the dual-antibody therapy, bamlanivimab and etesevimab, to states including Colorado, Connecticut and Illinois, Indiana.\nWith the Delta variant becoming the dominant strain, the prevalence of variants resistant to the therapy is steadily decreasing, the agency said\nBased on lab tests, the drugs administered together are expected to retain activity against the Delta variant, but not against Delta plus and variants first identified in Brazil, South Africa and Colombia, it said.\nThe department had in June paused its distribution after the therapy failed to show effectiveness against the coronavirus variants that were first identified in Brazil and South Africa.\nThe supply of standalone etesevimab to be paired with existing supply of bamlanivimab is also being resumed to some states.\nRegeneron's antibody therapy REGEN-COV, and GlaxoSmithKline Plc and partner Vir Biotechnology's\nsotrovimab may be used in all states, territories, and U.S. jurisdictions as they are likely to be effective against most variants including Delta, the agency said.\nBamlanivimab and etesevimab, REGEN-COV and sotrovimab are authorized for use in people 12 years and above with mild-to-moderate infection and are at high risk for progression to severe COVID-19.","news_type":1},"isVote":1,"tweetType":1,"viewCount":384,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":4,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/813958354"}
精彩评论